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Background: Anti-nuclear antibodies (ANA) are suspected of having relevance to adverse reproductive events.
Methods: This study aims to investigate the potential effect of ANA on IVF/ICSI outcome and the therapeutic role
of prednisone plus low-dose aspirin (P + A) adjuvant treatment in ANA + patients. The first IVF/ICSI cycles without
P + A of sixty-six ANA + women were enrolled as the ANA + group, and the 233 first IVF/ICSI cycles of matched
ANA- women served as the ANA- group. The ANA + group was divided into the Titre < =1:320 subgroup and the
Titre > 1:320 subgroup. Twenty-one ANA + women with adverse outcomes in their first cycles (ANA + cycles
without P + A) received P + A adjuvant treatment for three months before the second IVF/ICSI cycle (ANA + cycles
with P + A). The clinical characteristics and the IVF/ICSI outcomes were compared, respectively, between 1) the
ANA + group and the ANA- group, 2) the Titre < =1:320 subgroup and the Titre > 1:320 subgroup, and 3) the ANA +
cycles without P + A and the ANA + cycles with P + A.
Results: No significant differences were observed between each of the two-group pairs in the clinical
characteristics. The ANA + group exhibited significantly lower MII oocytes rate, normal fertilisation, pregnancy and
implantation rates, as well as remarkably higher abnormal fertilisation and early miscarriage rates. The Titre < =1:320
subgroup’s IVF/ICSI outcomes were as poor as those of the Titre > 1:320 subgroup. After the P + A adjuvant treatment,
the number of two pro-nuclei, perfect embryos and available embryos, and the implantation rate increased
significantly.
Conclusions: These observations suggest that ANA could exert a detrimental effect on IVF/ICSI outcome that might
not be titre-dependent, and P + A adjuvant treatment could be useful for ANA + patients. This hypothesis should be
verified in further prospective randomised studies.
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A portion of infertile patients consistently fail to conceive
despite recurrent transfers of high-quality embryos. The
mechanism leading to this reproductive failure is still un-
clear. To investigate this failure, several researchers have fo-
cused on the association between autoimmune factors and* Correspondence: shengzhizhongxin@126.com
†Equal contributors
Centre for Reproductive Medicine, Department of Obstetrics and
Gynecology, Anhui Provincial Hospital affiliated with Anhui Medical
University, Hefei, Anhui 230000, China
© 2013 Zhu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orIVF/ICSI outcome, and the focus is especially directed to-
ward autoantibodies [1-5]. It has been reported that ANA
were relevant to adverse reproductive events, including re-
current spontaneous abortion, endometriosis, infertility,
IVF failure, and ovarian dysfunction [6-10].
In a broad sense, ANA are a group of autoantibodies
that target the entire cell including DNA, RNA and pro-
teins [11]. Most of the common nuclear antigens can be
found on the surface structures of apoptotic cells, and
these molecules with the phospholipids on the surface of
the apoptotic cells can induce an autoimmune reaction,. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antibodies (APA) or ANA [12,13]. A basic cellular ab-
normality, such as increased apoptosis or decreased
clearance of apoptotic cells might explain the increased
APA and ANA levels in individuals with autoimmune
diseases [14]. One iconoclastic theory that ANA such as
an anti-double strand DNA (anti-dsDNA) antibody,
anti-RNP antibody, or anti-ribosomal P protein antibody
could penetrate into living cells has been confirmed
in vivo and in vitro [15-17].
It has been suggested that ANA could impair oocyte
quality and embryo development, leading to reduced
pregnancy and implantation rates [7,10], and women
with recurrent pregnancy loss had a significantly higher
incidence of ANA than controls [9]. Shirota et al. [18]
found that the presence of the anti-centromere antibody
might interfere with the oocyte maturation from MI to
MII and impair the embryo cleavage potential. Embryo
development was severely impaired or failed when co-
cultured with IgG from ANA +women [19].
In our study, we retrospectively analysed IVF/ICSI
outcomes in ANA +women and compared them with
ANA-controls. Differing from previous reports, we stud-
ied the effects of prednisone plus low-dose aspirin (P +
A) adjuvant therapy in ANA +women before IVF/ICSI
cycles. The aim of this study is to investigate the poten-
tial effect of ANA and different ANA titres on IVF/ICSI
outcome, and to determine the role of adjuvant treat-
ment in these ANA + patients.
Methods
Patients
Patients who received IVF/ICSI treatment were recruited
from the Reproductive Medicine Centre of Anhui Pro-
vincial Hospital affiliated with Anhui Medical University
from October 2009 to September 2012.
In our centre, ANA, D-dimmer, platelet aggregation
test, anti-cardiolipin antibody (ACA), anti-beta(2)-glyco-
protein I antibody (A-β2-GPI), triiodothyrorine (T3),
thyroxine (T4), thyroid stimulating hormone (TSH) and
anti-thyroid antibody (ATA) detection examinations
were performed to exclude pre-thrombotic state and
autoimmune disease. The women positive for ANA and
without specific autoimmune diseases were provided
with information regarding the P + A adjuvant therapy
protocol, and after considering the advantages and dis-
advantages, they decided whether to receive the adjuvant
therapy before each cycle.
A total of seventy-three patients meeting the following
requirements: 1) with age not over 38 years, 2) with in-
fertility caused by tubal disorder and/or male factor or
unexplained infertility, 3) who have undergone IVF/ICSI
treatment with the standard long protocol, and 4) posi-
tive for ANA and negative for other antibodies wereenrolled in our study, wherein seven patients received
adjuvant therapy, and the remaining sixty-six patients
received no special medications before IVF/ICSI treat-
ment. The first IVF/ICSI cycles (28 IVF cycles and 38
ICSI cycles) of these sixty-six patients were enrolled as
the ANA + group.
For the controls, two hundred thirty-three patients 1)
with age not over 38 years, 2) with infertility caused by
tubal disorder and/or male factor, 3) who have under-
gone IVF/ICSI treatment with the standard long proto-
col in the same period as the ANA + patients, 4)
negative for any antibody, and 5) who haven’t received
any special medications before the IVF/ICSI treatment
were recruited in our study, and only the first IVF/ICSI
cycles (106 IVF cycles and 127 ICSI cycles) were en-
rolled as the ANA- group.
The exclusion criteria for both groups were as follows:
uterine malformation; hypothyroidism; hyperthyroidism;
chromosome abnormality of the couples; sexually trans-
mitted diseases (STD) with ureaplasma urealyticum,
mycoplasma, chlamydia, gonococcus, fungi, trichomonas
vaginalis, HIV or treponema pallidum; or autoimmune
diseases such as systemic lupus erythematosus, anti-
phospholipids syndrome, autoimmune thyroiditis, and
Sjogren syndrome. This study was approved by the Eth-
ics Committee of Anhui Provincial Hospital.
According to the ANA titres, the ANA + group was
divided into two subgroups, including the Titre ≤ 1:320
subgroup (46 cycles) and the Titre > 1:320 subgroup
(20 cycles). The clinical characteristics and the IVF/ICSI
outcomes were compared, respectively, between the
ANA + group and the ANA- group, and between the
two subgroups.
Adjuvant medications
Twenty-one of these 66 ANA + patients, who had poor
IVF/ICSI outcomes in their first treatment cycles, re-
ceived a daily oral dose of 10 mg of prednisone plus
100 mg of aspirin up to three months before the second
IVF/ICSI cycle, wherein 2 patients (9.5%) became ANA-
negative, and 19 patients (90.5%) remained ANA-
positive after treatment. These patients entered the IVF/
ICSI program immediately after three months of adju-
vant treatment and received the same long-protocol for
controlled ovarian stimulation (COH) as in the first cy-
cles. The one-paired comparison was performed be-
tween the first cycles (the ANA + cycles without P + A)
and the second cycles (the ANA + cycles with P + A).
ANA assay
The ANA were detected using the indirect immuno-
fluorescence (IFT) method on the human epithelial
(HEp-2) cell substrate. Serum samples from the patients
were prepared at various dilution factors as follows:
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bated with fixed HEp-2 cells. The ANA could react with
the antigens of the Hep-2 cell substrate, forming
antigen-antibody complexes bound to the cell nucleus.
Temporarily, fluorescein-labelled antihuman immuno-
globulin was added and fluorescein-labelled antibody-
antigen-antibody complexes were formed and detected
by using fluorescence microscopy. The ANA were de-
fined as positive when the signal could be detected in
the nucleus with the serum diluted at 1:100 and the titre
of the ANA correlated with the highest serum dilution
factor that allowed for observing the fluorescence. The
nuclear patterns were observed using the Olympus
BX51 fluorescence microscope and all the antibodies
kits were purchased from Euroimmune Company
(Germany).
IVF/ICSI protocol
A long pituitary down-regulation protocol was used in
all the patients. A long-acting gonadotropin-releasing
hormone agonist (GnRH-a, Diphereline; Ipsen Pharma
Biotech, Signes, France) was injected intramuscularly in
the mid-luteal phase of the preceding cycle of gonado-
tropin (Gn) stimulation. After the complete pituitary
down-regulation, recombinant human FSH (Gonal-F,
Merck Serono SA, Geneva,Switzerland) was injected for
COH and urinary gonadotrophin (Menotrophins for In-
jection, LIVZON, China) was added in the late-follicle
phase. Human chorionic gonadotropin (HCG, LIVZON,
China) at a dose of 10000 IU was injected when at least
two follicles had reached 18 mm in mean diameter or
more than three follicles had reached 17 mm, and the
serum estradiol (E2) levels indicated more than 250 pg/
ml/mature follicle. The oocytes pick-up (OPU) was
performed transvaginally 36 h after the HCG injection.
The selection of fertilisation program, IVF or ICSI,
was based on the semen condition on the day of oocyte
retrieval. The oocyte was considered to be fertilised nor-
mally if a second polar body was extruded or if two pro-
nuclei (2PN) were observed 16 hours after insemination.
Embryo quality is primarily assessed by the day 3 em-
bryo grading system in our centre. The day 3 embryos
were evaluated based on the number and size of their
blastomeres and the degree of fragmentation as follows:
Grade 1: 6–8 even, equally sized blastomeres without
fragmentation of the blastomeres; Grade 2: 6–8 even,
equally sized blastomeres, and less than 20% fragmenta-
tion of the blastomeres; Grade 3: 4–6 uneven or irregu-
larly shaped blastomeres, and 20-50% fragmentation of
the blastomeres; Grade 4: the embryos are considered
non-viable with more than 50% fragmentation or with
even lysed, contracted or dark blastomeres. The embryos
graded 1 and 2 were considered good-quality or perfect
embryos, and the embryos graded 1, 2 and 3 wereconsidered available embryos. Two to three good-quality
embryos were initially selected for transfer (ET).
Progesterone supplementation by daily intramuscular
injection of 40 mg/day for the initial three days and
60 mg/day for the following days (approximately three
months) was administered from the day of the oocyte re-
trieval. Pregnancy was diagnosed by a positive blood test
for β-hCG at 14 days after the embryo transfer. Clinical
pregnancy was confirmed by the detection of a gesta-
tional sac with a foetal heartbeat by transvaginal ultra-
sound examination 14 days later.
Statistical analysis
The statistical analysis was performed using SPSS ver-
sion 13 statistical software. The continuous data were
described as the mean ± sd and compared using the
Mann–Whitney U rank sum test for two independent
samples or the Wilcoxon signed ranks test for the paired
samples. The rates were compared using the Chi square
test and Fisher’s Exact Test when appropriate. The dif-




The ANA + group and the ANA- group had no signifi-
cant differences in the age, duration of infertility, BMI,
basal hormone levels, days of ovarian stimulation, total
Gn dose, serum E2 level and endometrial thickness on
the day of the HCG injection (Table 1).
The Titre ≤ 1:320 subgroup and the Titre > 1:320 sub-
group also showed no significant differences in the age,
duration of infertility, BMI, basal hormone levels, days
of ovarian stimulation, total Gn dose, serum E2 level
and endometrial thickness on the day of the HCG injec-
tion (Table 2).
The ANA + cycles without P + A and the ANA + cy-
cles with P + A had similar days of ovarian stimulation,
total Gn dose, serum E2 level and endometrial thickness
on the day of the HCG injection (Table 3).
Fertilisation and embryo development in the ANA +
group and the ANA- group
The proportion of cycles using the ICSI fertilisation pro-
gram was similar in the ANA + and ANA- groups (57.6%
vs. 54.5%, p = ns). The semen parameters (i.e., the semen
volume, sperm concentration and progressive motility) on
the day of OPU were not significantly different in the ICSI
cycles and IVF cycles, respectively, between the two groups.
The MII oocytes rate (78.1% vs. 82.6%) and the normal
fertilisation rate in the ICSI/IVF cycles (70.5% vs. 83.1%,
and 66.1% vs. 76.0%) in the ANA + group were signifi-
cantly lower than those in the ANA- group, whereas the
opposite case occurred for the abnormal fertilisation rate
Table 1 Basal characteristics in the ANA + group and the ANA- group
Variables ANA + group ANA- group P
Patients 66 233 ns
Age (yrs) 32.33 +/− 4.25 31.41 +/− 3.84 ns
BMI (kg/ m2) 21.72 +/− 2.58 21.77 +/− 3.04 ns
Duration of infertility (yrs) 5.06 +/− 2.66 4.73 +/− 3.10 ns
bFSH (IU/L) 7.15 +/− 1.84 7.06 +/− 2.00 ns
bLH (IU/L) 4.61 +/− 2.85 4.41 +/− 2.16 ns
bE2 (pg/ml) 46.41 +/− 19.60 48.82 +/− 19.39 ns
Days of ovarian stimulation 12.21 +/− 2.36 12.65 +/− 2.18 ns
Total Gn dose (U) 2464.77 +/− 78.71 2399.25 +/− 803.25 ns
E2 levels on HCG day (pg/ml) 3014.28 +/− 1337.26 2952.86 +/− 1401.69 ns
Endometrial thickness on HCG day (mm) 10.46 +/− 1.64 10.96 +/− 2.04 ns
P < 0.05 was considered to be statistically significant.
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2.33%). There were no significant differences between
the groups in the cleavage rate and perfect and available
embryo rates (Table 4).
IVF/ICSI outcomes in the ANA + group and the
ANA- group
The implantation rate (9.09% vs. 36.8%) and the clinical
pregnancy rate (17.3% vs. 56.5%) in the ANA + group
were significantly lower than those in the ANA- group,
whereas the early miscarriage rate (44.4% vs. 9.62%)
showed the opposite result (Figure 1-a).
Fertilisation and embryo development in the titre ≤ 1:320
subgroup and the titre > 1:320 subgroup
The MII oocytes rate (73.6% vs. 80.4%) and the normal
fertilisation rate in the ICSI/IVF cycle (64.1% vs. 73.6%
and 57.6% vs. 68.3%) in the Titre > 1:320 subgroup were
lower than those in the Titre ≤ 1:320 subgroup but with-
out significance. The abnormal fertilisation rate in theTable 2 Basal characteristics in the titre ≤1:320 subgroup and
Variables Titre ≤1:32
Patients 46
Age (yrs) 31.72 +/− 4
BMI (kg/ m2) 21.96 +/− 2
Duration of infertility (yrs) 4.98 +/− 2.6
bFSH (IU/L) 7.00 +/− 2.0
bLH (IU/L) 4.68 +/− 3.1
bE2 (pg/ml) 45.97 +/− 21
Days of ovarian stimulation 12.52 +/− 2
Total Gn dose (U) 2553.0 +/− 83
E2 levels on the HCG day (pg/ml) 3017.61 +/− 14
Endometrial thickness on HCG day (mm) 10.40 +/− 1
P < 0.05 was considered to be statistically significant.IVF cycles (10.20% vs. 2.75%) in the Titre > 1:320 sub-
group was higher than that in the Titre ≤ 1:320 sub-
group. There were no significant differences between the
subgroups in the cleavage rate and the perfect and avail-
able embryo rates (Table 5).
IVF/ICSI outcomes in the titre ≤ 1:320 subgroup and the
Titre > 1:320 subgroup
No significant differences were observed between these
subgroups in the implantation rate, clinical pregnancy
rate and early miscarriage rate (Figure 1-b).
Fertilisation, embryo development and outcomes in the
ANA + cycles without P + A and the ANA + cycles
with P + A
The semen parameters (i.e., the semen volume, sperm
concentration and progressive motility) on the day of
OPU were not different significantly in the ICSI cycles
and the IVF cycles, respectively, between the ANA + cy-
cles without P + A and the ANA + cycles with P + A.the titre > 1:320 subgroup
0 Titre > 1:320 P
20 -
.12 33.75 +/− 4.30 ns
.55 21.16 +/− 2.63 ns
5 5.20 +/− 2.75 ns
2 7.49 +/− 1.33 ns
1 4.46 +/− 2.22 ns
.09 47.43 +/− 16.12 ns
.30 11.50 +/− 2.40 ns
8.50 2261.25 +/− 619.50 ns
04.05 3006.64 +/− 1203.62 ns
.74 10.60 +/− 1.42 ns
Table 3 Basal characteristics in the ANA + cycles without P + A and the ANA + cycles with P + A
Variables Without P + A With P + A P
Patients 21 21 -
Age (yrs) 31.71 +/− 3.61 - -
BMI (kg/ m2) 21.53 +/− 2.23 - -
Duration of infertility (yrs) 4.62 +/− 2.44 - -
bFSH (IU/L) 7.38 +/− 2.10 - -
bLH (IU/L) 4.57 +/− 2.46 - -
bE2 (pg/ml) 52.85 +/− 24.40 - -
Days of ovarian stimulation 12.22 +/− 2.14 11.95 +/− 2.13 ns
Total Gn dose (U) 2719.64 +/− 808.35 2567.86 +/− 722.85 ns
E2 levels on HCG day (pg/ml) 2704.12 +/− 1305.23 3139.39 +/− 1417.05 ns
Endometrial thickness on HCG day (mm) 10.58+/− 1.93 10.59 +/− 2.59 ns
P < 0.05 was considered to be statistically significant.
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therapy, the number of 2PN (4.86+/−2.89 vs. 7.05+/−3.17),
embryos (4.81+/−2.93 vs. 6.90+/−3.24), perfect embryos
(3.24+/−2.41 vs. 4.76+/−2.93) and available embryos
(3.62+/−2.22 vs. 5.76+/−3.25), as well as the pregnancy
rate (12.5% vs. 57.1%) and the implantation rate (6.06%Table 4 Fertilisation and embryo development in the ANA + g
Variables ANA + grou
OPU cycles (IVF + ICSI) 66 (28 + 38
ET cycles 52
Proportion of ICSI program (%) 57.6 (38/66
Semen volume (ml, ICSI cycles) 3.46+/−0.7
Sperm concentration (×106/ml, ICSI cycles) 16.86+/−13.
Sperm progressive motility (%, ICSI cycles) 11.97+/−9.7
Semen volume (ml, IVF cycles) 3.67+/−0.8
Sperm concentration (×106/ml, IVF cycles) 65.33+/−44.
Sperm progressive motility (%, IVF cycles) 40.28+/−16.
Retrieved oocytes 9.73 +/− 5.0
MII oocytes rate (%, ICSI cycle) 78.1 (285/36
Normal fertilisation rate (%, ICSI cycle) 70.5 (201/28
Abnormal fertilisation rate (%, ICSI cycle) 4.91 (14/28
Normal fertilisation rate (%, IVF cycle) 66.1 (183/27
Abnormal fertilisation rate (%, IVF cycle) 4.33 (12/27
Cleavage rate (%) 97.7 (375/38
Perfect embryo rate (%) 63.7 (239/37
Available embryo rate (%) 78.7 (295/37
Transferred embryos/cycle 2.12 ± 0.55
P<0.05 was considered to be statistically significant.
Note: Sperm with progressive motility, including those that move fast in a straight
motion (grade b). MII oocytes rate = M II oocytes/total oocytes in the ICSI cycle; nor
oocytes in the IVF cycle; abnormal fertilisation rate = 1PNs + multi-PNs/total M II oovs. 27.9%) increased significantly. The early miscarriage
rate was not statistically analysed because of the small
number of cases (Table 6).
The mean number of embryos for transfer per cycle
(2.76 +/− 0.58 vs. 2.06 +/− 0.44, P = 0.008) in the cycles
with P + A was higher than that in the cycles withoutroup and the ANA- group
p ANA- group P
) 233 (106 + 127) -
184 ns







3 10.38 +/− 4.15 ns
5) 82.6 (1112/1346) 0.047
5) 83.1 (924/1112) <0.001
5) 0.36 (4/1112) <0.001
7) 76.0 (815/1073) <0.001
7) 2.33 (23/1073) 0.041
4) 98.5 (1713/1739) ns
5) 66.5 (1139/1713) ns
5) 82.9 (1420/1713) ns
2.11 ± 0.38 ns
line (grade a) and that move forward but tend to travel in a curved or bent
mal fertilisation rate = 2PNs /total M II oocytes in the ICSI cycle or 2PNs/total
cytes in the ICSI cycle or 1PNs + multi-PNs/total oocytes in the IVF cycle.
Figure 1 Pregnancy outcome in IVF/ICSI cycles. (a) The IVF/ICSI outcome in the ANA + group and the ANA-group. In the ANA + group,
the implantation rate (9.09% vs. 36.8%) and the clinical pregnancy rate (17.3% vs. 56.5%) decreased significantly, and the early miscarriage rate
(44.4% vs. 9.62%) increased markedly more than in the ANA- group. (b) The IVF/ICSI outcome in the Titre ≤1:320 subgroup and the Titre > 1:320
subgroup. No significant differences were found between the two subgroups in the implantation rate, the clinical pregnancy rate and the early
miscarriage rate. * P < 0.05, ** P < 0.01.
Zhu et al. Reproductive Biology and Endocrinology 2013, 11:98 Page 6 of 9
http://www.rbej.com/content/11/1/98P + A (Table 6). The increased pregnancy rate in the cy-
cles with P + A might be because of the medication ef-
fect and/or the greater number of embryos for transfer
per cycle. It appeared that the pregnancy rate was not an
appropriate indicator for evaluating the medication
effect.
Discussion
For several years, detection of autoantibodies has been
recommended in clinical practice for women with infer-
tility including the detection of ANA, APA and ATA. A
link of APA with recurrent pregnancy loss has been
established, and treatment based on anticoagulation such as
subcutaneous heparin is effective [3]. As an organ-specific
autoantibody, ATA affect pregnancy outcome negatively
by damaging the thyroid function, and the thyroxinTable 5 Fertilisation and embryo development in the titre ≤ 1
Variables Titre ≤ 1:32
OPU cycles 46
ET cycles 33
Retrieved oocytes 9.96 +/− 5.0
MII oocytes rate (%, ICSI cycle) 80.4 (193/24
Normal fertilisation rate (%, ICSI cycle) 73.6 (142/19
Abnormal fertilisation rate (%, ICSI cycle) 5.18 (10/19
Normal fertilisation rate (%, IVF cycle) 68.3 (149/21
Abnormal fertilisation rate (%, IVF cycle) 2.75 (6/218
Cleavage rate (%) 97.6 (284/29
Perfect embryo rate (%) 63.7 (181/28
Available embryo rate (%) 78.2 (222/28
Transferred embryos/cycle 2.09 +/− 0.4
P < 0.05 was considered to be statistically significant.replacement therapy is efficacious in preventing foetal loss
for patients with recurrent miscarriage [1,2]. However,
the potential correlation between ANA and IVF/ICSI
outcome and specific medication are less reported.
Previous reports showed that ANA were relevant to
adverse reproductive events including recurrent spon-
taneous abortion, endometriosis, infertility, IVF failure
and ovarian dysfunction [6-10]. One recent study pro-
posed that ANA might impair oocyte quality and em-
bryo development, leading to reduced pregnancy and
implantation rates [10]. A further exploration [20] simi-
larly suggested that IVF outcomes were markedly poorer
in ANA + women, and this effect became worse with an
increased level of serum ANA.
In this study, we found that the presence of ANA in
serum predicted an adverse IVF/ICSI outcome, primarily:320 subgroup and the titre > 1:320 subgroup
0 Titre > 1:320 P
20 -
19 -
4 9.20 +/− 5.08 ns
0) 73.6 (92/125) ns
3) 64.1 (59/92) ns
3) 4.35 (4/92) ns
8) 57.6 (34/59) ns
) 10.2 (6/59) 0.034
1) 97.8 (91/93) ns
4) 63.7 (58/91) ns
4) 80.2 (73/91) ns
6 2.16 +/− 0.69 ns
Table 6 Fertilisation, embryo development and outcome in the ANA + cycles without P + A and the ANA + cycles
with P + A
Variables Without P + A With P + A P
OPU cycles (IVF + ICSI) 21(11 + 10) 21 (11 + 10) -
ET cycles 16 21 -
Semen volume (ml, ICSI cycles) 3.54+/−0.81 3.09+/−0.87 ns
Sperm concentration (×106/ml, ICSI cycles) 14.64+/−11.21 16.34+/−10.65 ns
Sperm progressive motility (%, ICSI cycles) 12.87+/−10.97 15.34+/−11.56 ns
Semen volume (ml, IVF cycles) 3.44+/−0.93 3.64+/−0.83 ns
Sperm concentration (×106/ml, IVF cycles) 62.56+/−43.78 66.23+/−39.23 ns
Sperm progressive motility (%, IVF cycles) 46.89+/−15.45 43.89+/−17.68 ns
Retrieved oocytes 8.10 +/− 3.95 9.24 +/− 4.10 ns
MII oocytes 6.50 +/− 4.09 7.20 +/− 3.99 ns
Two pro-nuclei 4.86 +/− 2.89 7.05 +/− 3.17 0.004
Perfect embryos 3.24 +/− 2.41 4.76 +/− 2.93 0.037
Available embryos 3.62 +/− 2.22 5.76 +/− 3.25 0.008
Embryos 4.81 +/− 2.93 6.90 +/− 3.24 0.006
Transferred embryos/cycle 2.06 +/− 0.44 2.76 +/− 0.58 0.008
Pregnancy rate (%) 12.5 (2/16) 57.1% (12/21) 0.006
Implantation rate (%) 6.06 (2/33) 27.9 (16/58) 0.013
Early miscarriage rate (%) 100 (2/2) 25 (3/12) -
P < 0.05 was considered to be statistically significant.
Zhu et al. Reproductive Biology and Endocrinology 2013, 11:98 Page 7 of 9
http://www.rbej.com/content/11/1/98reflecting the lower rates of MII oocytes and normal fer-
tilisation and the reduced rates of implantation and clin-
ical pregnancy, as well as the increased rates of
abnormal fertilisation and early miscarriage. The cleav-
age rate and the perfect and available embryo rates were
not significantly different between the ANA +women
and the controls, which was a finding that did not co-
incide with that of Ying Y et al. [10]. We found that
ANA-titre ≤1:320 women had as poor IVF/ICSI out-
comes as the ANA-titre > 1:320 women, and only the ab-
normal fertilisation rate in the IVF cycles in the ANA-titre
> 1:320 women was significantly higher. These results
did not suggest the titre-dependent effect of ANA on
IVF/ICSI outcomes, in agreement with Hasegawa et al.
[21] and Taniguchi et al. [22].
In general terms, abnormal autoimmune conditions
may impair all stages of fertility, leading to ovarian and
testicular failure, implantation failure or pregnancy loss
through different putative mechanisms [5]. It has been
proposed that APA and A-β2-GPI could result in throm-
bosis of placental blood vessels, dysfunctions of tropho-
blasts in the peri-implantation period or an imbalance of
maternal hormones [23-25]. Unlike APA and A-β2-GPI,
the mechanism by which ANA determine reproductive
failure remains speculative. Hasegawa et al. [21] held
that ANA did not target specific organs and only
presented as an abnormal degree of autoimmunity,
based on their findings that the adverse IVF outcomewas not ANA-titre dependent. One recent well designed
study [26] demonstrated that the presence of APA, ANA
or ATA in recipients using donor oocytes had no
negative effect on pregnancy, implantation or miscar-
riage, which suggested that implantation failure might
be because of poor-quality oocytes that may lead to a
subsequent embryo development disorder. One in vivo
test [27], in which anti-centromere antibodies were
microinjected into mouse oocytes, showed the anti-
centromere antibody could interfere with chromosome
congression in the pro-metaphase. Shirota K et al. [18]
considered that anti-centromere antibodies might in-
filtrate oocytes and lead to centromere dysfunction
during meiosis and mitosis and impair the transition
from MI to MII during oocyte maturation. Ying Y et al.
[20] has confirmed that ANA exist in follicular fluid and
embryos in ANA + patients, and serum and follicular
fluid ANA negatively correlated with the number of
high-quality embryos. The embryos co-cultured with IgG
extracted from ANA+women were found to be severely
impaired or even died [19].
Ando et al. [28] administered low-dose prednisolone
(5 mg/d) or dexamethasone (0.5 mg/d) daily during the
entire IVF cycle until the pregnancy test was performed
in 51 lVF-ET cycles of patients positive for ANA, anti-
DNA antibody, and/or lupus anti-coagulant (LAC),
as well as 29 IVF-ET cycles of patients negative for
any antibodies and discovered significant increases of
Zhu et al. Reproductive Biology and Endocrinology 2013, 11:98 Page 8 of 9
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positive patients with corticosteroid treatment but not
in the antibody-negative patients. Hasegawa et al. [21]
administered prednisolone (10 mg/d) plus low-dose
aspirin (81 mg/d) to ANA + and/or APA + women from
the first day of COH until pregnancy was confirmed by
ultrasonography and discovered that the ANA+women
with treatment had significantly better outcomes of IVF-
ET (40.6% pregnancy rate and 20.3% implantation rate).
Taniguchi et al. [22] administered prednisolone (15–60
mg/d) starting from the first day after OPU for 5 days in 56
IVF-ET cycles of 24 ANA + women and 167 IVF-ET
cycles of 96 ANA-women and found the implantation
rate and clinical pregnancy rate improved significantly
in the ANA + woman but not in the ANA-women,
which coincides with the findings of Ando et al. One
previous prospective study administered prednisone
plus aspirin for 4 weeks before IVF treatment to 52
women positive for ACA, ANA, anti-dsDNA antibody,
rheumatoid factor, and/or LAC and ultimately obtained a
satisfactory clinical pregnancy rate (32.7%) [29]. The
present study pretreated ANA+women with prednisone
(10 mg/d) plus low-dose aspirin (100 mg/d) (i.e., P + A)
for three months before IVF treatment and observed that
the ANA + cycles with P + A had markedly more 2PN,
high-quality and available embryos, and an increased
implantation rate. Our study also showed that the ANA
titre was not relevant to the IVF/ICSI outcome and the
adjuvant treatment was not closely related to the reduc-
tion of the serum ANA titre, which is in agreement with
Hasegawa et al. [21]. In this study and that of Hasegawa
et al. [21], women positive for autoantibodies were ad-
ministered a 10-mg daily dose of prednisone or prednis-
olone, and this dosage is too low to reduce the
autoantibody titres. Thus the corticosteroid effect may
be derived from another mechanism such as an anti-
inflammatory action or the regulation of immune cells
as in the reduction of NK cells [21]. Low-dose aspirin
for its anti-thrombotic effect may reduce uterine and
intraovarian vascular resistance, improve blood perfu-
sion and increase oocyte maturation, the high-quality
embryos rate, and the implantation rate [21]. Although
these five studies including the present work demon-
strated a beneficial effect of corticosteroid or cortico-
steroid plus aspirin therapy, an ideal protocol for this
adjuvant therapy (i.e., the indication of the patients, the
drug selection and dosage, and the timing of com-
mencement and end) requires further investigation.
In this study, we observed the detrimental effect of
ANA on IVF/ICSI outcome and the beneficial effect of
prednisone plus low-dose aspirin adjuvant treatment for
ANA + patients. The comparison between the first IVF/
ICSI cycle to a subsequent one would unavoidably yield
bias, which is the limitation of our study. To minimisethe bias, we rigorously selected the subjects, and there
was a long interval between the first and the second
IVF/ICSI cycles of at least 3 months. In our future work,
we will attempt to perform a placebo-controlled, double
blind, and prospective study.
Conclusions
These observations suggest that ANA could exert a det-
rimental effect on the IVF/ICSI outcome that may not
be titre-dependent, and prednisone plus low-dose aspirin
adjuvant treatment could be useful in ANA + patients.
This hypothesis should be verified in placebo-controlled,
double blind, and prospective studies.
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